The mean expression of platelets P-selectin in patients with thalassemia major and thalassemia intermedia was significantly higher than that in controls and patients with thalassemia minor. However, its expression was significantly higher in patients with thalassemia intermedia than in those with thalassemia major. Annexin V also showed a positive correlation with P-selectin, and both markers positively correlated with regularity of blood transfusion.
Background:
Laboratory data suggest that acute myeloid leukemia AML originates from
a rare population of cells, termed Leukemic Stem Cells (LSCs) or leukemia-initiating cells, which
are capable of self-renewal, proliferation and differentiation into malignant blasts. There is a
universal agreement that LSCs lie within the CD34+ compartment of hemopoietic cells and most of
leukemic stem cells express the interleukin-3 alpha chain receptor, CD123 and lack CD38. This
study aimed to estimate the expression of LSC phenotype in AML patients and to correlate it with
response to induction therapy.
Methods:
A cohort of 41 patients older than 15 years with newly diagnosed de novo AML were
enrolled in this study. They were obtained from the National center of hematology in Baghdad and
Baghdad teaching hospital between February and July 2013. The expression of CD34, CD38 and
CD123 was assessed by multi-color flow cytometry. LSC positive (LSC+) samples must express
CD34 and CD123 and lack the expression of CD38 in >1% of cells. French American British
(FAB) classification system was used in this study.
:
After four weeks of induction therapy; three groups were found: those who reached the Complete
morphological Remission (CR), those who failed to reach CR and those who died before the
assessment of morphological remission. The last two groups were merged for statistical purposes.
Results:
After the course of induction therapy, 41.46% of patients had complete morphological
remission while 58.54% of the studied patients failed to reach complete remission. The Complete
Remission (CR) rate was higher (53.33%) in patients who were negative for LSC phenotype than
patients who were positive for LSC phenotype (34.61%).
Conclusions:
LSCs were expressed in 63.41% of AML cases and were in approximate distribution
in FAB M3 and non-M3 patients. The expression of LSC phenotype was associated with poor
response to induction therapy in AML patients.
Background: Chronic lymphocytic leukemia(CLL) is a monoclonal malignancy characterized by an accumulation of small and mature looking B lymphocytes in the blood, bone marrow and other tissues, and is typically characterized by expression CD5+, CD23+, CD22 -, CD79b-, with weak expression of surface immunoglobulin (sIg). Two major clinical staging systems (Rai and Binet staging), that developed to estimate prognosis in CLL. However both these systems are unable to prospectively distinguish the rapidly developing patients from those appreciated to remain with a stable disease for decades. Several publications reported the prognostic important of 13q deletion in patients with chronic lymphocytic leukemia. 13q deletion is the most important cytogenetic abnormalities detected by Fluorescence In situ Hybridization in CLL patients and represent a good prognostic marker with 60% of patients alive after 5 years as compared with 27% for patients with a normal FISH analysis. Aims of the study: To investigate 13q deletion in patients with chronic lymphocytic leukemia by using FISH technique. To correlate the presence of 13q deletion with hematological and clinical prognostic markers including complete blood picture, absolute lymphocyte count, and modified Rai staging.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.